By Frank Prenesti
Date: Tuesday 19 Mar 2024
LONDON (ShareCast) - (Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.
AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 11,042.00p |
Change Today | -164.00p |
% Change | -1.46 % |
52 Week High | 13,276.00p |
52 Week Low | 9,501.00p |
Volume | 2,329,887 |
Shares Issued | 1,550.29m |
Market Cap | £171,184m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 9 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 30 |
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 08-Aug-24 | 22-Feb-24 |
Paid | 09-Sep-24 | 25-Mar-24 |
Amount | 100.00¢ | 197.00¢ |
Time | Volume / Share Price |
16:09 | 179,211 @ 11,160.00p |
16:51 | 488 @ 11,042.00p |
16:51 | 142 @ 11,042.00p |
16:35 | 3,725 @ 11,042.00p |
16:35 | 75 @ 11,042.00p |
You are here: research